GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Kingworld Medicines Group Ltd (HKSE:01110) » Definitions » Research & Development

Kingworld Medicines Group (HKSE:01110) Research & Development : HK$0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Kingworld Medicines Group Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Kingworld Medicines Group's Research & Development for the six months ended in Jun. 2024 was HK$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0 Mil.


Kingworld Medicines Group Research & Development Historical Data

The historical data trend for Kingworld Medicines Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kingworld Medicines Group Research & Development Chart

Kingworld Medicines Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 18.78

Kingworld Medicines Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Kingworld Medicines Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kingworld Medicines Group  (HKSE:01110) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Kingworld Medicines Group Research & Development Related Terms

Thank you for viewing the detailed overview of Kingworld Medicines Group's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Kingworld Medicines Group Business Description

Traded in Other Exchanges
N/A
Address
198 Daxin Road, 8th-9th Floor, Block A, Majialong Chuangxin Building, Nanshan District, Guangdong Province, Shenzhen, CHN, 518016
Kingworld Medicines Group Ltd is engaged in Distribution sales of pharmaceutical and healthcare products such as branded imported pharmaceutical and healthcare products in Hong Kong and the PRC, and Manufacturing and sales of electrotherapeutic and physiotherapeutic devices and general medical examination devices carried out in the PRC. It derives the majority of its revenue from Distribution sales of pharmaceutical and healthcare products segment.
Executives
Chan Lok San 2101 Beneficial owner
Zhao Li Sheng 2101 Beneficial owner
Tricor Trust (hong Kong) Limited 2301 Trustee
Sinopharm Capital Limited 2201 Interest of corporation controlled by you
Sinopharm Healthcare Fund L.p. 2101 Beneficial owner
Sun Hill Capital Investments Limited 2201 Interest of corporation controlled by you
Wu Aimin 2201 Interest of corporation controlled by you
Sun Hill Capital Investments Limited 2201 Interest of corporation controlled by you
Wu Aimin 2201 Interest of corporation controlled by you

Kingworld Medicines Group Headlines

No Headlines